| 2.67 -0.08 (-2.91%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.39 | 1-year : | 3.62 |
| Resists | First : | 2.9 | Second : | 3.09 |
| Pivot price | 2.67 | |||
| Supports | First : | 2.59 | Second : | 2.16 |
| MAs | MA(5) : | 2.67 | MA(20) : | 2.67 |
| MA(100) : | 2.67 | MA(250) : | 2.76  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 14 | D(3) : | 14 |
| RSI | RSI(14): 60.3 | |||
| 52-week | High : | 4.74 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BFRA ] has closed above bottom band by 50.0%. Bollinger Bands are 0% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.1 - 3.12 | 3.12 - 3.13 |
| Low: | 2.57 - 2.58 | 2.58 - 2.6 |
| Close: | 2.65 - 2.67 | 2.67 - 2.69 |
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Sat, 14 Oct 2023
Seth T. Goldsamt - McGuireWoods
Mon, 14 Feb 2022
Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs - Yahoo Finance
Thu, 09 Dec 2021
Biofrontera sees TAM of $4 Bln for lead product Ameluz: CEO Erica Monaco - AlphaStreet
Thu, 19 Mar 2020
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's ... - Yahoo Finance
Mon, 14 Oct 2019
An Up-Close Look At Biofrontera... - RTTNews
Mon, 25 Mar 2019
Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 3 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 21 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | -56 % |
| Operating Margin | -35.1 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 14.1 % |
| Gross Profit (p.s.) | 0.94 |
| Sales Per Share | 0.98 |
| EBITDA (p.s.) | -0.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -4.28 |
| PEG Ratio | 0 |
| Price to Book value | 3.51 |
| Price to Sales | 2.7 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2021-03-03 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|